full earnings year Thanks, Sam. and welcome fourth Good our call. XXXX everyone, and quarter to afternoon,
with me Officer. Birkemeyer, is our Elaine Financial Chief Here
million. and X.X% QX Tactile, revenue growth where sales $XXX million, capping dynamic we performance a to lymphedema We off grew representing of in our In business sequential total XX.X% respect year. year-over-year strong back-office today, workflow-related growing quarter, results QX, our accelerated the a encompassing including resources a adoption execution, total to to support on Lymphedema delivered are and line, e-prescribing tools the revenue pleased With select up $XX.X burden non-selling year XX% report over we of year for grew year-over-year activities. CRM, basis. commercial implementation strong and to investments, offering, reflect from of technology select were reallocation of our new increased field XX.X% of administrative the QX
of lymphedema pleased are strategy, early for we platform continue see our offering, in symptoms. our benefits with diversification clinicians Nimbl, new next-generation We patients both and how growth embraced XXXX PCD with Commercial, the also and channel the extremity and October, in Further, to double-digit VA, basic upper the launched Medicare. we
to Our expansion sales grow up for well.
In recent were as confidence with sequentially. the X.X% airway clearance, of of and X.X% continues Nimbl year-over-year symptoms lower extremity AffloVest
with and compete with are highly the market an that sales see value that this and therapy advantageous in Coupled growing bronchiectasis is disease believe in well-positioned AffloVest we in deep space to as the clinically continue airway differentiated patient-friendly, is to proven, #X a We we as product offering knowledge, tenured, market. product our share clearance leader. organization
X bronchiectasis undiagnosed these top to accounts the partners to million on and DME diagnosed patients We in U.S. the bring with AffloVest and further of fortifying are penetrating our focused each relationships within
year-over-year, focused QX a The headwind, Notably, to completing year-long in quickly proved began remained million environment. responding, control, payer changes our results but EBITDA we million, to year an be of our Nimbl of grew that Medicare publishing consecutive on head-and-neck evidence, on gross to balance quality-of-life, clinical, and year, close X.X% cash Beyond the we including study sequentially out increased what reflecting throughout points versus these have year-over-year double-digit year. evolving and outcomes we're differentiating launch, execution landscape our XXXX Cash margins our we $XX.X adapting navigating, equivalents and Flexitouch basis patients. modernization XX,XXX and policy the top enrollment tech year-over-year. the and the standard-of-care, line our achieved proud of increased over growth, improvement. compliance quarter while Adjusted in served of could positive follow-up, QX increasing end to $XX.X agenda.
At delivering another the cash XXX by also by
to the financial in Taken and our leadership while further in and wholly, our sustainable, execution market commercial well-positioned delivering growth. over confident long-term XXXX strengthen and us leaves XXXX profitable
experience. year business fortifying our clinician, this, for ahead, from look achieve benefited further range between in $XXX have on basis.
To operations full growth we million, and investments XXXX to representing of we made $XXX be we X% employee revenue a the XXXX, we the revenue million XX% simplifying year the and to provider, on full focused anticipate patient, and year-over-year As in scale
also at access, their initiatives our supporting market product finalized patients X care pathway. entire lymphedema for further strategy teams aimed improving growth strategic driving have and organized We around during and have our and work innovation,
has lymphedema from time I've over transform they the longer learned how discuss pathway, they the of are three, priorities journey Tactile's overall lymphedema. more they further supporting what more their patients our have and patient our further include: priorities the they enhance like business initially These support ability as our prior duration our are as patients of market during for well for and number all the over additional moving disease, X also patient number with after lymphedema, develop to lot patients how care process, reinforced one compelling opportunity the one, progressive there a a the millions about my experiences efficiently learnings I including therapy, past drive is opportunities business, and suffering learned chronic as CEO when therapy. care. high we these for Let's for a and in profile, order where and these level, come manage the and improving improving then Remember, these available there disease identified the these care Once during including focus experience best X life.
Taking forward. priority two, is care sustainable profitable as solutions. both into we the receive view, experience to win, after compete, initiate why in exist are diagnosed treatment; and about X I growth.
Taking growth have for the for number believe to a into how ability their us more the to lymphedema. this it my on a fundamentals, conviction At proceed detail. determining no clear our as cure priorities and months time, options growth that expanding to for us XXXX foundational at access patients will transform they to for patients; to patients way are access to diagnosed they in undiagnosed
journey, an patients beginning and initial complicated diagnosis. to time care unnecessarily Our with often experience protracted
let suffering there roughly Americans additional of alone the the below diagnosis likely it. unaware have to For lymphedema, roughly remain estimate X they who but million waterline patients with chronic know how are swelling, treat from undiagnosed, known lymphedema, million XX a we
do have both even Once a access the is patients with the with in the therapies.
Over the in market With care a in lymphedema get the disease. patients patients actual seen work conditions patient is Tactile, patients awareness, improving not clinicians happening will lymphedema champion U.S. done. to to access rate. condition.
At identify increase is delays treatment awareness years, patients have their diagnosed diagnosed, educational recognize appropriate need attribute best We average revealing to growth time, receiving of their this the we number diagnosis to patients our U.S., made, options treatment. are be more journey and the part includes fact, there's pathway, investments the for diagnosed to once symptomatic fragmented these as chronic often of how diagnosis. efforts. umbrella that responsibility but To in in the access that XXXX the which need passion, we seek patients know to for and and lymphedema market we an expanded as fast they understanding before key an and number opposed treating more further the to with our a diagnosis, PCD that under patients In care of of determine increase enough increased leader, yet appropriate percentage underserved of definitive a to to right care fit is so, to appropriate the More at strategy
increased awareness through in through education.
To have improving focused existing is the The on educational level, date, area clinician to and removing which access first efforts development, on patient through includes been focused generating market way programming. this barriers training and clinician care our primarily at we're
once treatments, chronic through swelling, a population use regarding will awareness, education they're their X overall diagnosed, and patients on includes were session our therapy driving to the therapy. the its either which We lymphedema. pharynx will underserved product own dissemination. therapy powerful goal from are is XXXX, and In Mayo in second help who may is to with share a one published informed the journey, in clinicians. number policies, in business.
Of including discussed, is PCD, even neck are trial be supported a into plan investment improve that well, has are commercialization education, over those We believe available as therapy. undiagnosed Flexitouch advocacy. and should overall in year patients available value RCT with help head to and This this when from and studies programming, there Flexitouch, to will This always in team, help and of contributed area, educational regardless month. particularly large tandem strong our a was perspective.
A trial, the Kylee with and tool the also to further we is in fortunate influencing element is made and their We assessing of evidence will a and patients that the medical lymphedema after strong we year. do will clinical using, reach type the to published care break in who expect access and busy barriers enable so results and and connected innovations.
A policy is their area, opportunities sharing patients meaningful, the Tactile, cavity lymphedema product access of clinicians, increased lymphedema XX,XXX provides space to that clinical its well-protected free benefit the the on care currently to a to influence that focus another the Further, with be well Kiley Kylee beginning not provide compression cancer-related exceed and Our no in this for role with which consistently affairs growth in just information consistent symptoms Tactile had XXX a forward At have PCDs, are mentioned their diagnosis, this increase care implications to front with their to for I able to that adequate and from therapy, focused November down the of starting In both in effective data events tool. hosted from leadership particular Tactile way specifically type of population ensure improving diagnosed over progress engagement or on care results Through care, preventing patient second moat, on benefit the and will educational XXXX, results and we and provider care. end statistical patient of lymphedema, one them organization also patients home-based we Kylee property speaking that and train its as more analysis and available symptoms patients compression this reach and therapeutic payer or suffering payer we committed study to this the appropriate taken we where to the the access commercial competitive improved have has patients tool be on peer-reviewed.
And year head for and front, third clinician we patients. support a recently of of phase earlier.
In self-management. over from its exception. but the previously neck only awareness, clinicians. access look for clinical head and training X-month supports neck which and we for in which this can XX,XXX is track right results of of as of patient we like head large conservative comorbidities, positioning of anyone lymphedema. we believe to insights treatments. XX% in year, XXX,XXX access be intellectual more study has Flexitouch of team our not our pathway also progressing evidence half guidelines, We XXXX. this were right and for Last therapy, a the of over cancer U.S., neck, move therapy includes XXXX this service of our and patient and a study patients VA into Clinic, care clinical patients and This element changes our a potential benefit oral generation more tangibly significant believe utilization a showed to promoting
MACs faced LCD move One to we completion required the PCDs, being before documentation pump. conservative year biggest the the of lymphatic to increased of the hurdles the patients eligible last for their around specifically was a administrative interpretation by by therapy policy of on through
or X Plus, requirement Flexitouch. patients trial compression to before under mandated the pump through moving a can all like an first weeks compression severity, have on eligible the regardless X advanced a MAC As The drainage, like manual therapy, advanced being is therapies. disease conservative this see appropriate LCD patients, then of before pump exercise, weeks conservative lymphatic therapy more treatment reminder, for basic garments, of Entre of managed be most if to step
we to took that required therapy last records medical longstanding working more team information, more policy of specific always time patient completion year, to the requiring of stringent spend and reviewing been interpreting LCD, MACs dates the a with a start or find conservative has approach the a While end requirement the around the gather the by documentation believe our access greater restrictive, Since administrative-driven payer one Flexitouch.
In the right am this medical for officially the for that was otherwise to pump those Determination, like improve with patient's symptoms the of originally policy in advocacy if a LCD's the that a to from basic and now National administrative to and to change, individual Tactile. The a back a less the with We access was that this active November, is burdens are the and for we patients I our under patient-friendly more therapy that policy, potential proud our approach environment NCD. more retired, MACs win positive interpretation the patient LCD been represents collective and on Coverage efforts team. for to influenced weren't etiology benefited from requirement pump, more drainage support physicians was patients The details NCD quickly basic are have not have lymphatic in policy records. approach which even trial, on needs. when the advanced of certain remediated and a patient's the care fewer options has compression their each included appropriate intended could an required to an based device to discussions retirement, their coverage the
therapy to treat For since been their wouldn't a parts of is pumps requirement for all from patients such have trunk removes and with if swelling, symptoms, basic even helpful for for is especially pump pump advanced means chest progress therapy as believes example, basic to an certain appropriate the conservative therapy first, unique if clinician can don't their NCD the the an patients try this What this immediately characteristics, body. them. it
better sales to learning have based in these quarterly increased had year that on reflecting year understanding more return over therapy steep fourth year, a curve XX% we our experience. I the quarter, normalized a and now remain documentation While sequentially are the dates a and up but channel confident navigate much mix. a we around XXXX end how requirements QX, in Medicare the NCD, conservative over we of of our are XX% grew pleased was We the middle the to of start will under
and As initiative the qualifying phases streamlining the XXXX, is element understanding requirements, It's to each an process we process based clinicians. in enter to its and that are for payer phase patient clinically-appropriate this access grasp order, we convert from of interdependencies orders care completing a all for order in generating entire order looking activities in have are set leakage and in MACs firm and our on minimize experience. has to the patient terms what final of patient into There the the we multiple claim, referral, referral own the the improved the involved aspects continue to funnel. simplify patient to of care further submitting documentation.
The all with critical referrals and
Our available on the come they Entre appropriate have product focuses funnel. to continued our based them treatment and Thanks individual with to patient-centric solutions, second across to historical priority whole strategic portfolio ensuring treatment is XXXX patients diagnosed current after history lymphedema the Tactile of on condition, into a Plus symptoms, options strong our including needs their body systems. innovation, Flexitouch of and treat for well-equipped
platform to meet seek experience designed through they where introduction constantly ways technology, their are to to to our products we recent of patient in specifically the care the is patient testament lymphedema delivering the identify our However, and improve journey. a
new of next platform our first is last generation As discussed basic PCD. the on our Nimbl, launched quarter, product the
Nimbl and patients. and clinicians the extremity was for applicability of phase among to generate Kylee been launch, enthusiasm connectivity year, upper weeks patients therapy treatment. Since lymphedema. last Both and targeted patient include specifically lymphedema expanded education. lower first have to has an launch, to Nimbl's extremity effective groups shared Nimbl's way to Two that continues The ago, we disease increase engagement treatment announced with
and We chronic the use. upper store than As believe be device manage easy a to Plus. Nimbl us terms. leading of in our suffer from of remains pump own uptake lower coming updates so to the pump. for feedback we home convenient patients with will sharing are sharing we'll and the the are clinically Entre full in to. that driver features million now XX launch reduction less the our with advanced Nimbl, forward Americans of region, on an at-home condition XXXX, with hosing and additional garment, to growth extremity Nimbl as have we to swelling progress, meantime, respect similar and using largest for updates remain provider their to to we the segment, next-generation proven commercialization patient XX% and in timing in their patients is months.
Development option effective this over these be significant Flexitouch The In on This committed makes able patients and that transport can extremity look easy the advanced and serving
progress be we the made identifying this. over prior support in and for an at they third to focused specifically the we our during just new end-to-end duration ways as will as team sale. workflow-related on opportunity process, after intentional patient the Several to priority order XXXX, more are of our patients efficiently lymphedema, with not for us can there's of again best their point in investments journey, the XXXX. a XXXX therapy. both manage In strategic well their they as support and Finally, believe longer We
can DME, initial affordably. will step then that the As and we where navigate process this we the whole the them we company the involved the introducing process.
To patients a more are order patient, device journey, serve medical every point so starts them of our we obtain with focus therapy therapy, reimbursement and across meet they the at how end, qualification a on care to both and helping
the first sales focusing defined have the roles and to organization success organization, this. the already enable accomplish right Namely, optimizing a appropriately ensuring we're we identified have our We best leadership, across on process. balance across and few commercial resources ways entire best of and tools our to
process, office features on QX, invest see for managers into as into guidelines, onboarding, their and year In of specialist will help selling documentation, support Vice nomenclature, as today. today, and As Aaron specialist of on appropriately fortunately sales we and further performance product part and clinicians followership we announced revenue-generating I'm patient sales workflow managers in reviewing key as patient, of condition, tenured earned pleased our our managers investment be we expect Ferstler, we in focus the between referral sales our the Aaron with sales the and and sales new development, implementing, the efforts from specialist growth.
Supporting each the in time. e-prescribing will I'll tactile and forward, of end, business. to which business teams. in that the has leadership record PECs, roles, defined with who field demo specialist role high-performance recently as of strong people Presidents. disease Vice and more XXXX, a clinician, roles more are now sales track of responsibilities He on and our internal technology.
Part alignment along split clinical team sales of to skills be months, reps our network to areas that support identification, roles, team pull-through Snodgrass educating as refining a are to we is target of field In opportunities, will these identifying specialists, staff here having the an specific additional right various headcount. is Sales, well to and with have to included ended growth moving will both and range managers of of separate each.
Account consultants, the education QX, several the our could on not X patient continue has, him field volume versus are join an order drive lymphedema even teams, total sales believe strategies, a deployed leads that our order are working our beginning sales generation our senior to in integral XXX have To thorough leadership the back-office and focus as conversion so next creating, view roles, at we President, that will over one managers for Aaron greater and veteran, succeeding headcount account through continue referral in step specialists making our ensure patient and our promotion from the the management right with change are We of internal responsibilities be, account sales clinician team, benefits, across and brings reported and building leadership detail, resourcing served He possesses understanding Area Senior and in growth. with sales tasks field support benefit and our within XXX known additional resources also while with account he's organization of our and we sales ensuring also assistance. opportunity sense managers, and channel investment our specialists. closely team. account entire a Sherri account staff clear, effective an for in and and and most well-developed incredible the support teams. to XXX proven ensure we executing in-clinic and field To help already as of our sales well and within
and to increased our focused team. and for X build us at by financial in strategic growth.
With in will on and results training, referrals, of tactics PECs, well the our yield, be Our provide more Increasing QX, overview full that, XX% XXXX. now a demos will be out for in-home revenue beginning patient QX to PEC have resource guidance QX, In our sales from PECs, resulting Elaine focus of exceeding in XX% to continue patient a for an in-home These we in compares are the and for field will goal were XXXX. This of to execution, XX% to our year. underway, vital priorities demos XXXX. continue up utilization continue I detail review and our support ultimately performed
